Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.43 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.41 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.41 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.41 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359024 | 0.98 | EPHX1 (0.66) | EPHX1CYP2C19CYP2D6CYP1A2PKM | |
| SCHEMBL23977 | 0.98 | EPHX1 (0.66) | EPHX1CYP2C19CYP2D6CYP1A2PKM | |
| SCHEMBL27689551 | 0.98 | EPHX1 (0.66) | EPHX1CYP2C19CYP2D6CYP1A2PKM | |
| SCHEMBL16881947 | 0.98 | EPHX1 (0.66) | EPHX1CYP2C19CYP2D6CYP1A2PKM | |
| Hydrochloric Acid SCHEMBL222654 | 0.96 | EPHX1 (0.63) | EPHX1CYP2C19CYP2D6CYP1A2PKM | |
| Lactic Acid SCHEMBL27998199 | 0.87 | EPHX1 (0.54) | EPHX1CYP2C19CYP2D6CYP1A2LMNA | |
| Ethylbenzene SCHEMBL27718807 | 0.86 | EPHX1 (0.62) | EPHX1CYP2C19CYP1A2LMNAMEN1 | |
| Paraben SCHEMBL10942097 | 0.83 | LMNA (0.53) | EPHX1CES2CES1LMNAMEN1 | |
| Bromide SCHEMBL30809291 | 0.83 | CYP2C19 (0.57) | EPHX1CYP2C19CYP2D6SMN1; SMN2LMNA | |
| SCHEMBL7909103 | 0.82 | EPHX1 (0.61) | EPHX1CYP2C19CYP2D6CYP1A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | ELIXIR MEDICAL CORPORATION (US) | 2018-11-13 | — | — | US | claimed |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2017-05-04 | — | — | US | claimed |
| CN-105380947-A | Macrolide compound and use method thereof | ELIXIR MEDICAL CORP | 2016-03-09 | — | — | CN | claimed |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION | 2015-12-10 | — | — | US | claimed |
| US-20130230571-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2013-09-05 | — | — | US | claimed |
| EP-2624834-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | Elixir Medical Corporation (US) | 2013-08-14 | — | — | EP | claimed |
| EP-1480677-B8 | COMPOSITION FOR STABILIZING HYALURONIC ACID | CARL ZEISS MEDITEC SAS (FR) | 2012-05-23 | — | — | EP | claimed |
| WO-2012047813-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2012-04-12 | — | — | WO | claimed |
| EP-1480677-B1 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2012-02-29 | — | — | EP | claimed |
| US-8088789-B2 | Administering hemiketal ring and seco-macrocyclic lactones; immunosuppressive, anti-proliferative, anti-fungal and anti-tumor | ELIXIR MEDICAL CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| US-20100130544-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHODS AND COMPOSITIONS | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2010-05-27 | — | — | US | claimed |
| US-20100086579-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2010-04-08 | — | — | US | claimed |
| WO-2010040064-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2010-04-08 | — | — | WO | claimed |
| WO-2009114010-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2009-09-17 | — | — | WO | claimed |
| EP-2026807-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHOD AND COMPOSITIONS | Universita' Degli Studi di Torino (IT) | 2009-02-25 | — | — | EP | claimed |
| US-20080234309-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | ELIXIR MEDICAL CORPORATION (US) | 2008-09-25 | — | — | US | claimed |
| WO-2007135574-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHOD AND COMPOSITIONS | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2007-11-29 | — | — | WO | claimed |
| EP-1480677-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2004-12-01 | — | — | EP | claimed |
| US-20030133986-A1 | Compositions for stabilizing poly (carboxylic acids) | TSAO FU-PAO (US) | 2003-07-17 | — | — | US | claimed |
| WO-2003043660-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | CHRM2, CHRM1, CHRM5 | SLC6A3 4136/4885CHRM2 1/4885ADRA2C 1406/4885 |
| US-20170119741-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | SLC6A3 3439/4885CHRM2 1/4885ADRA2C 1405/4885 |
| US-20150352089-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | SLC6A3 3482/4885CHRM2 1/4885ADRA2C 1422/4885 |
| US-20080234309-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | CHRM2, CHRM1, CHRM5 | SLC6A3 3439/4885CHRM2 1/4885ADRA2C 1405/4885 |
| US-20100086579-A1 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE | VIP, MIF, MYLK | SLC6A3 4881/4885CHRM2 1578/4885ADRA2C 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.